Genmab A/S High Paying Jobs, Compensation Information and Expert Network Connections

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US.

The company has 5 approved antibodies used in 7 marketed products, covering cancer indications and autoimmune diseases:

Proprietary, marketed with Seagen:

Marketed by partners:

Furthermore both Genmab and the partners have a whole range of antibody programs, building on Genmab technologies, in clinical and pre-clinical development. Genmab have several late stage clinical programs for tisotumab vedotin and epcoritamab. The partners have, among others, clinical programs for daratumumab, amivantamab, and teprotumumab.